Selenium NHCs Derivatives as Anticancer Agent

Abstract

N-Heterocyclic Carbene (NHC) selenium compounds have emerged as a promising class of anticancer agents with unique chemical structures and mechanisms of action. This review provides an overview of the potential of NHC selenium derivatives as effective therapeutic agents in cancer treatment. Furthermore, we summarize the findings from preclinical studies that demonstrate the anticancer activity of NHC selenium compounds against various types of cancer, including breast, lung, colon, and prostate cancer. These complexes exhibit selective cytotoxicity towards cancer cells while sparing normal cells, making them attractive candidates for targeted therapies. In conclusion, N-Heterocyclic Carbene selenium compounds exhibit promising anticancer activity and hold great potential as novel therapeutic agents. Further research and development efforts are warranted to optimize their structures, elucidate their precise mechanisms of action, evaluate their efficacy in clinical settings, and ultimately enhance their impact on cancer treatment.